News & Resources

Olshan Represents Pharmacyclics in Successful $207.2 Million Public Offering

March 8, 2013

Olshan represented Pharmacyclics Inc., a NASDAQ-listed clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases, in a $207.2 million overnight public offering of 2.2 million shares of its common stock. Adam Finerman, Jonathan Deblinger, Erik Syvertsen, Jason Soncini, and Marisa Lusthaus comprise the Olshan team that represented Pharmacyclics in this matter.